Browsing by Author "Okay, Müfide"
Now showing items 1-4 of 4
-
Aggressive Clinicopathological Course Of Myeloma With T(3;16) (Q21;Q22) Cytogenetic Abnormality
Bozkurt, Süreyya; Okay, Müfide; Haznedaroğlu, İbrahim (2019) -
Mitoxantrone-Melphalan Conditioning Regimen For Autologous Stem Cell Transplantation In Relapsed/Refractory Lymphoma
OKAY, Müfide; BÜYÜKAŞIK, Yahya; DEMİROĞLU, Haluk; MALKAN, Ümit Yavuz; ÇİFTÇİLER, Rafiye; ALADAĞ, Elifcan; AKSU, Salih; HAZNEDAROĞLU, İbrahim Celalettin; SAYINALP, Nilgün; ÖZCEBE, Osman İlhami; GÖKER, Hakan (2019)Background/aim High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become the standard approach for patients with relapsed/refractory Hodgkin’s lymphoma (HL) or non-Hodgkin’s lymphoma (NHL). ... -
The Impact Of Jak/Stat Inhibitor Ruxolitinib On The Genesis Of Lymphoproliferative Diseases
TÜRK, Can; OKAY, Müfide; TÜRK, Seyhan; TEMİRCİ, Elif Sena; JAVAD, Osama; AKSU, Salih; SAYINALP, Nilgün; HAZNEDAROĞLU, İbrahim Celalettin (2019)Background/aim Ruxolitinib, a JAK/STAT signaling pathway inhibitor targeted drug, has been approved for the controlling of disease symptoms and splenomegaly in patients with myeloproliferative neoplastic diseases. Recently, ... -
Tumor Lysis Syndrome Due To Targeting Of Hepatocellular Carcinoma Associated With Chronic Myelomonocytic Leukemia
Okay, Müfide; Çetik, Sıla; Haznedaroğlu, İbrahim C. (2019)